Oncopeptides AB Stock price

Equities

ONCO

SE0009414576

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 07:59:33 2024-03-28 am EDT 5-day change 1st Jan Change
6.5 SEK -2.40% Intraday chart for Oncopeptides AB +51.30% -15.14%
Sales 2023 35.2M 3.29M Sales 2024 * 105M 9.82M Capitalization 615M 57.46M
Net income 2023 -249M -23.27M Net income 2024 * -223M -20.84M EV / Sales 2023 18.7 x
Net cash position 2023 66.92M 6.25M Net cash position 2024 * 214M 19.98M EV / Sales 2024 * 3.82 x
P/E ratio 2023
-2.78 x
P/E ratio 2024 *
-3.61 x
Employees 57
Yield 2023 *
-
Yield 2024 *
-
Free-Float 89.19%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.40%
1 week+51.30%
Current month+34.69%
1 month+26.21%
3 months-14.83%
6 months-23.98%
Current year-15.14%
More quotes
1 week
4.61
Extreme 4.607
7.09
1 month
4.00
Extreme 4
7.88
Current year
4.00
Extreme 4
8.30
1 year
4.00
Extreme 4
11.94
3 years
3.40
Extreme 3.402
153.40
5 years
3.40
Extreme 3.402
215.00
10 years
3.40
Extreme 3.402
215.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 20-07-31
Director of Finance/CFO 50 Nov. 12
Chief Tech/Sci/R&D Officer 42 19-10-31
Members of the board TitleAgeSince
Chairman 76 18-05-16
Director/Board Member 63 11-12-31
Director/Board Member 61 17-01-31
More insiders
Date Price Change Volume
24-03-28 6.5 -2.40% 617,154
24-03-27 6.66 +26.18% 1,940,400
24-03-26 5.278 +3.78% 344,943
24-03-25 5.086 -5.81% 589,946
24-03-22 5.4 +20.89% 2,138,884

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:59 am EDT

More quotes
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company's lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock
  2. Equities
  3. Stock Oncopeptides AB - Nasdaq Stockholm